Skip to main content
Premium Trial:

Request an Annual Quote

Surmodics Buys Dx Substrate Developer BioFX in Deal Worth Up to $22.7M

NEW YORK (GenomeWeb News) - SurModics, a developer of drug-delivery and surface-modification technologies, said this week that it has acquired BioFX Laboratories in a deal worth up to $22.7 million.  
The agreement calls for SurModics to pay $11.3 million for BioFX, which makes substrates used by the in vitro diagnostics industry. SurModics said it could pay an additional $11.4 million on the achievement of certain revenue targets. 
SurModics said BioFX had revenues of $3.5 million in 2006, which represented growth of 16 percent over 2005, and added that the company is both “profitable and cash-flow positive.”
SurModics expects the acquisition to be accretive in fiscal 2008 and beyond.
BioFX sells both colorimetric and chemiluminescent substrates and other products for use in IVDs.
“By combining the BioFX products with our own,” said SurModics CEO Bruce Barclay, “we can offer more high-value critical components to a broader customer base in the in vitro diagnostics market."
SurModics is based in Eden Prairie, Minn., while BioFX is headquartered in Owings Mills, Md. The BioFX business will remain in Maryland but operate within SurModics’ In Vitro Technologies business unit in Minnesota.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.